0001171843-16-012251.txt : 20160923
0001171843-16-012251.hdr.sgml : 20160923
20160923170047
ACCESSION NUMBER: 0001171843-16-012251
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160921
FILED AS OF DATE: 20160923
DATE AS OF CHANGE: 20160923
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLDENBERG DAVID M
CENTRAL INDEX KEY: 0001029578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 161900398
MAIL ADDRESS:
STREET 1: UBS GLOBAL ASSET MANAGEMENT (US) INC.
STREET 2: 51 WEST 52ND STREET
CITY: NEW YORK
STATE: NY
ZIP: 10019
4
1
formfour.xml
OWNERSHIP DOCUMENT
X0306
4
2016-09-21
0
0000722830
IMMUNOMEDICS INC
IMMU
0001029578
GOLDENBERG DAVID M
C/O IMMUNOMEDICS, INC
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
1
1
0
0
See Remarks
Common Stock
2016-09-21
4
A
0
106061
0
A
3464631
I
See Footnote
Common Stock
2510565
D
Stock Option (right to buy)
3.30
2016-09-21
4
A
0
199532
0
D
2023-09-21
Common Stock, par value $0.01 per share
199532
199532
I
See Footnote
The reporting person's spouse, Ms. Cynthia L. Goldenberg (also known as Cynthia L. Sullivan), President and Chief Executive Officer of the Company, was granted restricted stock units pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan, which vest as to 25% of the shares on the first anniversary of the date of grant and as to 6.25% of the shares on a quarterly basis thereafter.
Includes a total of 190,000 shares held as joint tenants by the reporting person and his spouse.
Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is a director. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.
The reporting person's spouse was granted stock options pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan, which vest as to 25% of the shares underlying the options on the first anniversary of the date of grant and as to 6.25% of the shares underlying the options on a quarterly basis thereafter.
Chief Scientific Officer, Chief Patent Officer, and Chairman of the BOD
/s/ David M. Goldenberg
2016-09-23